Astrazeneca Plc ADR (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 54,073,000 | 45,811,000 | 44,351,000 | 37,417,000 | 26,617,000 |
| Cost of Goods | 10,207,000 | 8,268,000 | 12,391,000 | 12,437,000 | 5,299,000 |
| Gross Profit | 43,866,000 | 37,543,000 | 31,960,000 | 24,980,000 | 21,318,000 |
| Operating Expenses | 33,863,000 | 29,350,000 | 28,203,000 | 23,924,000 | 16,156,000 |
| Operating Income | 10,003,000 | 8,193,000 | 3,757,000 | 1,056,000 | 5,162,000 |
| Interest Expense | 1,742,000 | 1,626,000 | 1,346,000 | 1,300,000 | 1,306,000 |
| Other Income | 430,000 | 332,000 | 90,000 | -21,000 | 60,000 |
| Pre-tax Income | 8,691,000 | 6,899,000 | 2,501,000 | -265,000 | 3,916,000 |
| Income Tax | 1,650,000 | 938,000 | -792,000 | -380,000 | 772,000 |
| Net Income Continuous | 7,041,000 | 5,961,000 | 3,293,000 | 115,000 | 3,144,000 |
| Minority Interests | 6,000 | 6,000 | 5,000 | 3,000 | -52,000 |
| Net Income | $7,035,000 | $5,955,000 | $3,288,000 | $112,000 | $3,196,000 |
| EPS Basic Total Ops | 2.27 | 1.92 | 1.06 | 0.04 | 1.22 |
| EPS Basic Continuous Ops | 2.27 | 1.92 | 1.06 | 0.04 | 1.20 |
| EPS Diluted Total Ops | 2.25 | 1.91 | 1.06 | 0.04 | 1.22 |
| EPS Diluted Continuous Ops | 2.25 | 1.91 | 1.06 | 0.04 | 1.20 |
| EPS Diluted Before Non-Recurring Items | 4.11 | 3.63 | 3.33 | 2.65 | 2.01 |
| EBITDA(a) | $16,691,000 | $13,580,000 | $9,237,000 | $7,586,000 | $8,311,000 |